Form 4: Cassava Sciences CFO Eric Schoen Reports Stock Option Grant

Chief Financial Officer Eric Schoen of Cassava Sciences Inc. reports the acquisition of stock options.

Summary

• Eric Schoen, the Chief Financial Officer of Cassava Sciences Inc., filed a Form 4 with the SEC.
• The filing reports a transaction on April 17, 2025, where Schoen acquired stock options.
• Schoen was granted options to purchase 100,000 shares of Cassava Sciences' common stock at an exercise price of $1.44.
• The options vest in four equal annual installments, with the first 25% vesting on April 17, 2026.
• The options expire on April 17, 2035.
• Following the reported transaction, Schoen directly owns options for 100,000 shares.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. The granting of stock options is a standard practice and generally viewed as a positive sign of aligning management interests with shareholders.

Positives

• The grant of stock options to the CFO aligns his interests with those of the shareholders.
• The vesting schedule encourages long-term commitment from the CFO.

Industry Context

Stock option grants are a common practice in the pharmaceutical industry to incentivize executives and align their interests with the long-term success of the company. This is especially true for companies like Cassava Sciences that are in the research and development phase.

Comparison to Industry Standards

• Stock option grants are a standard component of executive compensation packages in the biotechnology industry.
• Comparable companies like Biogen, Eli Lilly, and Pfizer also utilize stock options to incentivize their executives.
• The vesting schedule of four years is also typical in the industry, aligning with the long-term nature of drug development.

Stakeholder Impact

• Shareholders may view the stock option grant as a positive sign, aligning management's interests with the company's long-term success.
• Employees may see the grant as a sign of confidence in the company's future.

Key Dates

Keywords

Form 4, Stock Options, Eric Schoen, Cassava Sciences, SAVA, CFO, Beneficial Ownership